The DOI matches its Crossref record; 387 of the 389 references it cites were found in a registry or an index.
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Open accessAbstract
An estimated 20-25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,124
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978 · cited 1×
“Among European Caucasians, filaggrin mutations are associated with early-onset and severe AD (43).”
BackgroundBoehncke, W., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,609
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,586
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Kong, H. H., Oh, J., Deming, C., Conlan, S., Grice, E. A., Beatson, M. A., Nomicos, E., Polley, E. C., Komarow, H. D., Program, N. C. S., et al. (2012) · Genome Research · doi:10.1101/gr.131029.111 · Cited by 1,808 · cited 1×
“Patients with AD have a higher burden of Staphylococcus aureus which contributes to the inflammation (46).”
BackgroundHoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,679
Lundberg, I. E., Tjärnlund, A., Bottai, M., Werth, V. P., Pilkington, C., de Visser, M., Alfredsson, L. S., Amato, A. A., Barohn, R. J., Liang, M. H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211468 · Cited by 1,597
Zuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer‐Weber, B., Bangert, C., Ben‐Shoshan, M., Bernstein, J. A., et al. (2022) · Allergy · doi:10.1111/all.15090 · Cited by 1,263
Flagged first, then by citations
2 of the 389 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–159 of 159
Pemphigus‐ und Pemphigoid‐Erkrankungen: Klinik, Diagnostik und Therapie
Didona, D., Schmidt, M. F., Maglie, R., & Solimani, F. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15174_g · Cited by 2
Impact of inflammatory skin conditions on the biological profile of plasma rich in growth factor
Anitua, E., Tierno, R., de Lagrán, Z. M., & Alkhraisat, M. H. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102560 · Cited by 2
Toledo, M. D. G. T., Lazo, R. E. L., Domingos, E. L., Zein, A. K. E., Cobre, A. D. F., Borba, H. H. L., Ferreira, L. M., & Pontarolo, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106275 · Cited by 3
Simioni, Y. R., Usseglio, N. A., Butassi, E., Altube, M. J., Higa, L. H., Romero, E. L., Schilrreff, P., & Morilla, M. J. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106661 · Cited by 4
Kridin, K., Papara, C., Bieber, K., Luca, D. A. D., Klein, J. P., Ludwig, M. A., Curman, P., Vorobyev, A., Dempfle, A., & Ludwig, R. J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1429297 · Cited by 2
Tsoi, L., Dong, Y., Patrick, M. T., Sarkar, M., Zhang, H.-H., Bogle, R., Zhang, Z., Dand, N., Paulsen, M., Ljungman, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5724270/v1 · Cited by 2
“ISDs affect 15–20% of the global population, exhibiting marked differences in prevalence and clinical symptoms that are distinctly shaped by geographical locations and ancestry backgrounds 3,10 .”
Didona, D., Santos, A. M. S., Cunha, T., Hinterseher, J., Kussini, J., & Hertl, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1001120 · Cited by 1
“In patients with MMP, IgG antibodies against BP180 and BP230 are mostly detected by ELISA (4, 5).”
BackgroundInfluentialDistinct Variations in Gene Expression and Cell Composition across Lichen Planus Subtypes
Knoch, C., Baghin, V., Turko, P., Winkelbeiner, N., Staeger, R., Wei, K., Banzola, I., Mellett, M., Levesque, M. P., Kuendig, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179720 · Cited by 1
“It is one of the most common inflammatory skin diseases, with a prevalence of 0.1–1.2% [1,2] of the worldwide population.”
BackgroundInfluentialKuş, M. M., Yaray, O. C., Öztürk, P., & Mülayim, M. K. (2025) · Medicine · doi:10.1097/md.0000000000041747 · Cited by 1
“[13] We aimed to retrospectively evaluate the relationship between the disease activity and IGC, IG%, anti-Dsg1, anti-Dsg3, CRP levels, neutrophil-to-lymphocyte ratios (NLR), and platelet-to-lymphocyte ratio (PLR) in patients with pemphigus.”
Ferulic acid-loaded Nanoemulsion Gels: A strategy for enhanced skin delivery and reduced irritation
de Almeida, T. M., Kudrna, K. B., Biasuz, E., Spiazzi, C. C., Felix, I. R., Leite, D. C., Cossetin, L. F., Nogueira-Librelotto, D. R., Schaffazick, S. R., & da Silva, C. D. B. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107199 · Cited by 1
Salau, A. K., Shehu, M. S., Adisa, K. O., Olarewaju, O. I., & Adeyemo, A. A. (2025) · UMYU Scientifica · doi:10.56919/usci.2542.019 · Cited by 1
Cirstea, N., Radu, A.-F., Ţiţ, D. M., Radu, A.-F., Bungau, G. S., Endres, L. M., & Negru, P. A. (2025) · Bioengineering · doi:10.3390/bioengineering12080890 · Cited by 1
“Around 20–25% of individuals are impacted by persistent, non-infectious inflammatory skin conditions [1].”
State-of-the-Art Skin Disease Classification Using Ensemble Learning and Advanced Image Processing
Nirupama, & Virupakshappa, V. (2025) · Cybernetics & Systems · doi:10.1080/01969722.2025.2551843 · Cited by 2
Koster, N., van den Reek, J. M. P. A., de Jong, E. M. G. J., van Beugen, S., van Laarhoven, A. I. M., Haeck, I. M., de Bruin-Weller, M. S., Schuttelaar, M. L. A., Horváth, B., Gostyński, A., et al. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70311 · Cited by 1
Wen, H., Du, Y., Wang, W., Zhang, Z., Zheng, A., Khan, M. F., Lü, Y., & Lv, H. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.177278 · Cited by 1
Latest and Greatest in Inflammatory Skin Disease and Gut Microbiome
Curbelo-Paz, A., Lee, E. T., Sadur, A., D’Angelo, N., & Choudhary, S. (2026) · Dermato · doi:10.3390/dermato6020020 · Cited by 1
“Given that such diseases affect 15–20% of the population [10], understanding their causes and exploring therapeutic interventions is crucial.”
Mehri, Z., Nahidi, Y., Ramezani, B., & Torabi, S. (2024) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2023.0395 · Cited by 1
Arakeliian, M. K., & Luzhnov, P. V. (2023) · Systems and Technologies of the Digital HealthCare (STDH) · doi:10.1109/stdh59314.2023.10490949 · Cited by 1
“Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors [6].”
BackgroundEmtenani, S., Lebhar, H., Marquis, C. P., Ludwig, R. J., & Schmidt, E. (2024) · Experimental Dermatology · doi:10.1111/exd.15172 · Cited by 1
“10–12 Thus, there is an unmet clinical need for more effective, targeted treatments.”
Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
Godse, K. V., Girdhar, M., Jagadeesan, S., & Laiker, R. (2024) · IP Indian Journal of Clinical and Experimental Dermatology · doi:10.18231/j.ijced.2024.045 · Cited by 1
“11,12 A better understanding of therapeutics, public education, and support is needed for newer management strategies.”
BackgroundZhu, B., Li, J., Ni, Q., Yang, S., Yin, Z., & Yang, X. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00743-9 · Cited by 1
“The diverse etiologies and clinical presentations of IMIDs pose significant challenges in diagnosis and treatment, resulting in a substantial burden on patients [8].”
Abdelwadood, D., Fouad, Y. A., El-Khazragy, N. N., & Amr, A. E. H. (2025) · BMC Oral Health · doi:10.1186/s12903-025-06303-9 · Cited by 1
“The patients suffer from chronic burning sensation with episodes of remission and exacerbation; impairing their quality of life [24, 25].”
Dupilumab-Induced Generalized Lichen Planus: A Case Report
Feng, H.-S., Zhang, C., Guo, Y., Jia, Y.-N., Zhai, Y., Zheng, X.-R., Zhang, T., Zhu, B., Zhang, W., & Hua, G.-D. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s561924 · Cited by 1
Pemphigoiderkrankungen bei älteren Menschen
Moderegger, E. L., Schmitz, M. J., Ludwig, R. J., Sadik, C. D., & Schmidt, E. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05209-3 · Cited by 1
“Die Inzidenz der meisten Pemphigoiderkrankungen steigt im Alter, insbesondere die des bullösen Pemphigoids (BP), des Schleimhautpemphigoids (SHP) und des Anti-p200-Pemphigoids [53, 59].”
BackgroundInfluentialAcencio, M. L., Lopata, O., Hemedan, A. A., Dand, N., Weidinger, S., Paternoster, L., Brown, S., Rastrick, J. M. D., Smith, C. H., Hübenthal, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640747 · Cited by 1
“Among the most frequent chronic ISDs are atopic dermatitis (AD), psoriasis (PsO), acne, urticaria, lichen planus, and hidradenitis suppurativa (1).”
Soomro, R. B. K., Soomro, A. B., Wassan, S. M., Abbasi, F., & Memon, I. (2025) · Research Square · doi:10.21203/rs.3.rs-6419628/v1 · Cited by 1
Eldesoky, H. A. M., Abdelaziz, T. M., Eleryan, E. M., & Rady, S. E. (2023) · Egyptian Journal of Nursing and Health Sciences · doi:10.21608/ejnhs.2023.292139
Editorial: Case reports in dermatology
Recke, A., & Hashimoto, T. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1269802
“Rare diseases clearly show the limits that are still faced by modern medicine (3).”
BackgroundAjani, A. A., Olanrewaju, F. O., Enitan, A. O., FABUSUYI, O. T., Oripelaye, M. M., Oninla, O. A., & Olasode, O. A. (2023) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1304a262
“Inflammatory NCDs affect about 20 – 25% of the world population[39].”
BackgroundOral Bullous Lichen Planus – A Case Report
Islam, M. S., Islam, N., & Sharmeen, A. (2024) · Community Based Medical Journal · doi:10.3329/cbmj.v13i1.71090
Liu, Q., Zhang, Y., Xu, B., Jin, X., Yang, T., & Fan, L. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1235
“13 For instance, one study demonstrates that MALT1 forms a complex with B cell lymphoma/leukemia 10 (BCL10) to amplify the keratinocyte responses to several inflammatory cytokines, then stimulate the lymphocyte ‐ mediated psoriatic skin inflammation.”
BackgroundIncorporating Dermatologic Clinical Research Into Private Practice: A Review
Slater, K., & Fivenson, D. P. (2024) · Cureus · doi:10.7759/cureus.57733
Atopic March; The Skin is the Clue
Attia, E. A. S. (2024) · Journal of dermatology and clinical research. · doi:10.47739/2373-9371.dermatology.1157
A study to evaluate the effectiveness of Xyzal UC cream in participants with urticaria
Jain, A. K., Joshi, D. K., Bhagat, S. V., Sanghavi, A. P., Gala, M. Y. N., Muchhala, S., Katare, S., & Kotak, B. (2024) · Cosmoderma · doi:10.25259/csdm_100_2024
Yin, X., Shi, L., Li, H., & Long, J. (2024) · Advances in Dermatology and Allergology · doi:10.5114/ada.2024.142287
“Inflammation is a well-established feature of au - toimmune diseases, and the cytokine milieu in the serum of affected individuals may provide valuable insights into disease activity and potential response to treatment [16, 17].”
BackgroundIntroductory Chapter: New Challenges for Practionners, New Roads for Patients
Vereecken, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005493
Artificial intelligence-enabled precision medicine for inflammatory skin diseasesPreprint
Tang, A., Wei, M. L., Haemel, A. K., La, C., Sirota, M., & Lee, E. Y. (2025) · PubMed · doi:10.48550/arxiv.2505.09527 · Cited by 5
Pancatalytic biomaterials enable inflammation-related disease intervention
Jiang, X., & Chen, Y. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00408j
Soft Sensors for Disease Diagnosis
Hu, H., Su, Y., & Nan, K. (2025) · Wiley eBooks · doi:10.1002/9783527845507.ch3
Enhancing dermatology clinical trials: optimizing sites and strategies for success in India
Chandrashekar, B., Roopa, M. S., & Narayana, N. L. (2025) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20253341
AI-Driven Drug Development in Immunological Disorders
Esakkimuthu, B., Mani, M., Subramanian, P. D., Balasubramanian, B., Asirvatham, A. R., Philomenathan, A. P. J., Shanmugam, V., & Arumugam, V. A. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-5258-9.ch004
Sameera, A., Nizar, M. A. M., Hussaini, H. M., Cooper, P. R., Rich, A. M., & Seo, B. (2026) · Clinical and Experimental Dental Research · doi:10.1002/cre2.70330
“Calcineurin inhibitors have shown some promise, but they are not always shown to be more effective than steroids (Ujiie et al. 2022).”
Image-Based Skin Disease Classification Using Transfer Learning Model and Fusion Strategy
Yang, Y.-C., Hung, C., Chen, Y.-J., & Dai, P. (2025) · Adaptation, learning, and optimization · doi:10.1007/978-3-032-12362-6_3
Mai, W., Chen, X., Ye, W., Zhang, G., & 梁文瑜 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760388
A scRNA-seq atlas of chronic inflammatory skin diseasesPreprint
Gansberger, S., Oyarzun, I., Simon, M., Ziegler-Santos, S., Yuan, H., Bauer, W. M., Tschandl, P., Weninger, W., Strobl, J., Frech, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.15.725328
Synergistic approaches: Optimizing skin health through combination therapies
Rathee, N., & Yadav, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41640-8.00002-7
Şen, O. (2026) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2026.2692370
Brouer, I. C., Zani, A., Curman, P., Ludwig, R. J., & Thaçi, D. (2026) · Biomolecules · doi:10.3390/biom16081083
“Non-communicable, chronic inflammatory barrier diseases (CIBDs) include various immune-mediated inflammatory diseases (IMID) affecting different organ systems and im-Biomolecules posing substantial physical, psychosocial, and economic burdens on patients and healthcare systems [1,2].”
InfluentialCD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Groß, N., Jochimsen, A., Dräger, S., Theocharis, T., Recke, A., van Beek, N., Schmidt‐Jiménez, L. F., Krohn, S., Klausz, K., Bieber, K., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201825
Kpenou, F. C., Han, J. H., Fadel, M., Vo, T., Ju, H. J., Aarbaoui, T. E., Griffiths, C. E. M., Lim, H. W., French, L. E., Flohr, C., et al. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.07.017
Kercher, E. M., Sadiki, A., Liu, S., Essien, K. I., Scudiere, J., Finlay, W. J. J., Epperly, A. H., Zhou, Z. S., Spring, B. Q., & Harris, J. E. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.07.025
Work impact of immune‐mediated inflammatory skin diseases: A systematic review and meta‐analysis
Kpenou, F. C., Han, J. H., Fadel, M., Vo, T., Ju, H. J., Aarbaoui, T. E., Griffiths, C. E. M., Lim, H. W., French, L. E., Flohr, C., et al. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70653
Skowrońska, W., Kiełkiewicz, R. M., Kirzyc, M., Janowski, M., Kołodziejska, J., Michorowska, S., Dawidowski, M., Kolmas, J., Giebułtowicz, J., Granica, S., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119845
Cardinale, C. J., Liu, Y., Kevadia, A., Tobias, J. W., Kao, C., & Hakonarson, H. H. (2026) · Scientific Reports · doi:10.1038/s41598-026-66935-x
Shokr, H., Marwah, M. K., Tahan, M. A. A., Popek, O., & Sanchez-Aranguren, L. C. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10850-1
“However, long-term use of conventional topicals such as corticosteroids and calcineurin inhibitors is often associated with adverse effects, including epidermal thin - ning, barrier disruption, and tachyphylaxis [ 19].”
Pharmaceutical Market Analysis of Topical Semi-Solid Dosage Forms for Skin Disorders in Kazakhstan
Savelyev, A., Khrustalev, D. P., Викторовна, Л. И., Yedrissov, A., Khrustaleva, A., Kazantsev, V., Shapovalenko, S., Kiikbayev, M., Rusyaeva, P., & Perepelitsyna, K. (2026) · Pharmaceuticals · doi:10.3390/ph19091357
“…remain one of the most common human pathologies: according to various estimates, chronic non-viral inflammatory dermatoses affect 20–25% of the population, and at least one dermatological condition within the past 12 months has been reported in 43.35% of the adult population in Europe [12,13].”
InfluentialYang, Z., Liu, Y., & Yang, H. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004201
Curman, P., Fischer, E., Golaboska, J., Harms, K., Borowik, J., Huckshold, J., Löscher, C.-E., Nadjmabadi, M., Maeda, A., Pourrahimi, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1951015
Metadata
- Authors
- Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., Amber, K. T., Didona, D., Hertl, M., Recke, A., Graßhoff, H., Hackel, A., Schumann, A., Riemekasten, G., Bieber, K., Sprow, G., Dan, J., Zillikens, D., Sezin, T., Christiano, A. M., Wolk, K., Sabat, R., Kridin, K., Werth, V. P., & Ludwig, R. J.
- Affiliations
- Hokkaido University (JP)
- Tufts Medical Center (US)
- Universitätsmedizin Göttingen (DE)
- University Hospital Münster (DE)
- University of Lübeck (DE)
- Humboldt-Universität zu Berlin (DE)
- Rush University Medical Center (US)
- Philipps University of Marburg (DE)
- Philadelphia VA Medical Center (US)
- Columbia University Irving Medical Center (US)
- Charité – Universitätsmedizin Berlin (DE)
- Bar-Ilan University (IL)
- Corresponding author
- Ludwig, Ralf J.
- ORCID
- Ujiie, Hideyuki
- Rosmarin, David
- Schön, Michael P.
- Ständer, Sonja
- Boch, Katharina
- Metz, Martin
- Maurer, Marcus
- Schmidt, Enno
- Cole, Connor
- Amber, Kyle T.
- Didona, Dario
- Hertl, Michael
- Recke, Andreas
- Graßhoff, Hanna
- Hackel, Alexander
- Riemekasten, Gabriela
- Bieber, Katja
- Dan, Joshua
- Zillikens, Detlef
- Sezin, Tanya
- Christiano, Angela M.
- Wolk, Kerstin
- Sabat, Robert
- Kridin, Khalaf
- Werth, Victoria P.
- Ludwig, Ralf J.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2022-06-09
- Volume
- 9
- Pages
- 875492-875492
- ISSN
- 2296-858X (ISSN-L)
- PMC
- PMC9218547
- OpenAlex
- W4285740668
- Cited by
- 158
- References
- 389
- Citations by year
- 2026: 20 · 2025: 40 · 2024: 49 · 2023: 37 · 2022: 12
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (EXC 2167, FOR 2497, FOR 2690, RI/1056-11,, SFB 1526)
- National Institutes of Health (R01AR071653, R01AR076766)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII5_202301/1)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- chronic inflammatory skin disease, unmet medical needs, atopic dermatitis, psoriasis, urticaria, lichen planus, hidradenitis suppurativa, alopecia areata, vitiligo, pemphigus, pemphigoid diseases, cutaneous lupus erythematosus, dermatomyositis, autoinflammatory disease, systemic immunosuppression, biomarkers, treatment response prediction, early diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
